tiprankstipranks
BioGaia AB Class B (GB:0GTN)
LSE:0GTN

BioGaia AB (0GTN) Share Price & Analysis

1 Followers

0GTN Stock Chart & Stats

Day’s Rangekr0 - kr0
52-Week Rangekr91.55 - kr135.80
Previous Closekr115.19
Volume12.46K
Average Volume (3M)10.97K
Market Cap
kr11.63B
Enterprise Valuekr11.40B
Total Cash (Recent Filing)kr45.02M
Total Debt (Recent Filing)kr23.24M
Price to Earnings (P/E)31.8
Beta0.11
May 07, 2024
Dividend Yield1.26%
Share Statistics
EPS (TTM)3.62
Shares Outstanding100,982,310
10 Day Avg. Volume10,202
30 Day Avg. Volume10,966
Standard Deviation0.09
R-Squared0.11
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)27.56
Price to Sales (P/S)132.60
Price to Cash Flow (P/CF)6.00
P/FCF Ratio-546.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.00%1.49%1.55%96.96%
0.00%
Insiders
1.55% Other Institutional Investors
96.96% Public Companies and
Individual Investors

0GTN FAQ

What was BioGaia AB Class B’s price range in the past 12 months?
BioGaia AB Class B lowest share price was kr91.55 and its highest was kr135.80 in the past 12 months.
    What is BioGaia AB Class B’s market cap?
    Currently, no data Available
    When is BioGaia AB Class B’s upcoming earnings report date?
    BioGaia AB Class B’s upcoming earnings report date is May 07, 2024 which is in 9 days.
      How were BioGaia AB Class B’s earnings last quarter?
      BioGaia AB Class B released its earnings results on Feb 07, 2024. The company reported kr0.67 earnings per share for the quarter, beating the consensus estimate of kr0.59 by kr0.08.
        Is BioGaia AB Class B overvalued?
        According to Wall Street analysts BioGaia AB Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does BioGaia AB Class B pay dividends?
          BioGaia AB Class B pays a Annually dividend of kr1.9 which represents an annual dividend yield of 1.26%. See more information on BioGaia AB Class B dividends here
            What is BioGaia AB Class B’s EPS estimate?
            BioGaia AB Class B’s EPS estimate is kr0.96.
              How many shares outstanding does BioGaia AB Class B have?
              BioGaia AB Class B has 97,278,970 shares outstanding.
                What happened to BioGaia AB Class B’s price movement after its last earnings report?
                BioGaia AB Class B reported an EPS of kr0.67 in its last earnings report, beating expectations of kr0.59. Following the earnings report the stock price went up 8.979%.
                  Which hedge fund is a major shareholder of BioGaia AB Class B?
                  Currently, no hedge funds are holding shares in GB:0GTN
                  ---

                  BioGaia AB Stock Smart Score

                  N/A
                  Not Ranked
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Positive
                  20 days / 200 days
                  Momentum
                  22.84%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  18.25%
                  Trailing 12-Months
                  Asset Growth
                  5.38%
                  Trailing 12-Months

                  Company Description

                  BioGaia AB Class B

                  BioGaia AB engages in the development, marketing, and sale of probiotic products. It operates through the following segments: Pediatrics, Adult Health, and Other. The Pediatrics segment sells drops, oral rehydration solutions (ORS), digestive health tablets, and also royalties pertaining to pediatric products. The Adult Health segment include gut health tablets, oral health products, and offers cultures as an ingredient in a licensee's dairy product. The Other segment consists royalties from the collaboration with Nestlé and a few minor products, such as animal health products. The company was founded by Jan Annwall and Peter Rothschild in 1990 and is headquartered in Stockholm, Sweden.
                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AstraZeneca
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis